Philip Bhatt

Philip Bhatt leads biomarker-driven clinical trials evaluating PI3K and AKT inhibitors in solid tumors. His research has characterized genomic and proteomic predictors of response to PI3K pathway inhibitors across multiple tumor types beyond breast cancer. He has designed adaptive clinical trial protocols incorporating ctDNA monitoring to assess pharmacodynamic pathway inhibition and emerging resistance mechanisms. His clinical and translational work has advanced capivasertib, ipatasertib, and other AKT inhibitors in combination with endocrine therapy, chemotherapy, and immune checkpoint blockade.